Sangamo falls on 16-week data from gene editing trial

Sangamo Therapeutics Inc. (NASDAQ:SGMO) was off $4.50 (24%) to $14.55 on Wednesday after reporting that plasma iduronate 2-sulfatase (IDS) activity was below the level of quantification through 16 weeks in the Phase I/II CHAMPIONS trial evaluating SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter’s syndrome). The stock move translates to a loss in market cap of about $450 million.